S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer
Launched by SWOG CANCER RESEARCH NETWORK · Apr 9, 2004
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES: I. Assess the survival and response rate of patients with previously untreated extensive stage small cell lung cancer treated with paclitaxel, carboplatin, topotecan, and filgrastim (G-CSF). II. Determine the side effects and toxicity of this regimen in these patients.
OUTLINE: Patients receive topotecan IV over 30 minutes on days 1-4 and paclitaxel IV over 1 hour followed by carboplatin IV over 1 hour prior to topotecan on day 4. Patients receive filgrastim (G-CSF) subcutaneously once daily beginning on day 5 and continuing until blood counts recover. G-CSF must be discontinue...
Gender
ALL
Eligibility criteria
- • DISEASE CHARACTERISTICS: Histologically or cytologically proven, previously untreated extensive stage small cell lung cancer (SCLC) Brain metastases allowed if: Asymptomatic OR Previously treated with radiotherapy and/or surgery Measurable or evaluable disease outside the area of prior surgical resection or a new lesion must be present
- • PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy: Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.25 times upper limit of normal (ULN) SGOT or SGPT no greater than 2.5 times ULN Renal: Creatinine no greater than ULN Creatinine clearance at least 50 mL/min Other: Not pregnant or nursing Fertile patients must use effective contraception No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or any stage I or II cancer that is in complete remission
- • PRIOR CONCURRENT THERAPY: Biologic therapy: No prior systemic biologic therapy for SCLC Chemotherapy: No prior systemic chemotherapy for SCLC Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics No prior radiotherapy for SCLC Surgery: See Disease Characteristics At least 2 weeks since prior thoracic or other major surgery and recovered
About Swog Cancer Research Network
The SWOG Cancer Research Network is a leading cancer clinical trial organization dedicated to improving cancer treatment and outcomes through innovative research. Comprising a collaborative network of academic institutions, community hospitals, and cancer centers, SWOG conducts rigorous clinical trials that advance the understanding of cancer biology, prevention, and therapy. With a strong emphasis on inclusivity and diversity, SWOG aims to ensure that clinical research reflects the populations affected by cancer, ultimately striving to enhance patient care and quality of life. Through its commitment to scientific excellence and collaboration, SWOG plays a pivotal role in shaping the future of oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oklahoma City, Oklahoma, United States
Tucson, Arizona, United States
Los Angeles, California, United States
Los Angeles, California, United States
Orange, California, United States
Denver, Colorado, United States
Lexington, Kentucky, United States
Jackson, Mississippi, United States
Durham, North Carolina, United States
Cincinnati, Ohio, United States
Spartanburg, South Carolina, United States
Dallas, Texas, United States
Sacramento, California, United States
Wichita, Kansas, United States
San Antonio, Texas, United States
Phoenix, Arizona, United States
Atlanta, Georgia, United States
Kansas City, Missouri, United States
Maywood, Illinois, United States
Detroit, Michigan, United States
Long Beach, California, United States
Los Angeles, California, United States
Martinez, California, United States
Oakland, California, United States
Santa Rosa, California, United States
Travis Air Force Base, California, United States
Lexington, Kentucky, United States
New Orleans, Louisiana, United States
Jamaica Plain, Massachusetts, United States
Ann Arbor, Michigan, United States
Detroit, Michigan, United States
Springfield, Missouri, United States
Billings, Montana, United States
Columbus, Ohio, United States
Dayton, Ohio, United States
Kettering, Ohio, United States
Portland, Oregon, United States
Greenville, South Carolina, United States
Seattle, Washington, United States
Albuquerque, New Mexico, United States
Temple, Texas, United States
Honolulu, Hawaii, United States
Cleveland, Ohio, United States
Tucson, Arizona, United States
Little Rock, Arkansas, United States
Little Rock, Arkansas, United States
Denver, Colorado, United States
Fort Gordon, Georgia, United States
Decatur, Illinois, United States
Hines, Illinois, United States
Wichita, Kansas, United States
New Orleans, Louisiana, United States
Shreveport, Louisiana, United States
Boston, Massachusetts, United States
Detroit, Michigan, United States
Southfield, Michigan, United States
Biloxi, Mississippi, United States
Jackson, Mississippi, United States
Saint Louis, Missouri, United States
Albuquerque, New Mexico, United States
New York, New York, United States
Cincinnati, Ohio, United States
Oklahoma City, Oklahoma, United States
Portland, Oregon, United States
San Antonio, Texas, United States
Temple, Texas, United States
Salt Lake City, Utah, United States
Seattle, Washington, United States
Seattle, Washington, United States
Tacoma, Washington, United States
Phoenix, Arizona, United States
Kansas City, Kansas, United States
New Orleans, Louisiana, United States
Grand Rapids, Michigan, United States
Keesler Afb, Mississippi, United States
Fort Sam Houston, Texas, United States
Lubbock, Texas, United States
Salt Lake City, Utah, United States
Galveston, Texas, United States
Ann Arbor, Michigan, United States
Mobile, Alabama, United States
Kansas City, Kansas, United States
Shreveport, Louisiana, United States
Boston, Massachusetts, United States
Portland, Oregon, United States
Patients applied
Trial Officials
Frank Dunphy, MD
Study Chair
Duke Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials